Home
About
Overview
Sharing Data
ORCID
Help
History (87)
Factors Influencing Margin Clearance and the Number of Stages of Mohs Micrographic Surgery in Basal Cell Carcinoma: A Retrospective Chart Review.
Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
Deep sequencing of pre-translational mRNPs reveals hidden flux through evolutionarily conserved alternative splicing nonsense-mediated decay pathways.
Fabrication of surface-active antioxidant biopolymers by using a grafted scallop (Patinopecten yessoensis) gonad protein isolate-epigallocatechin gallate (EGCG) conjugate: improving the stability of tuna oil-loaded emulsions.
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
See All 87 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
Paul B, Rodriguez C, Usmani SZ. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 2022 Apr; 82(6):613-631.
View in:
PubMed
subject areas
B-Cell Maturation Antigen
Biological Therapy
Humans
Immunotherapy, Adoptive
Multiple Myeloma
Neoplasm Recurrence, Local
Standard of Care
authors with profiles
Saad Usmani MD